David Turner, BSc, PhD

Research Assistant Professor
Pathology and Laboratory Medicine

Lab: Rm 327, Hollings Cancer Center
Lab Phone: 843-792-1522
Fax: 843-792-3940

Send email to Dr. Turner

Education:

• Bsc (Hons) in Molecular Biology: 1993-1996, University of Newcastle Upon Tyne, England, UK.
• PhD in Biochemistry: 1997-2001, University of Newcastle Upon Tyne, England, UK.
• Post-Doctoral Fellowship: 2001-2002, University of Newcastle Upon Tyne, England, UK.
• Post-Doctoral Fellowship: 2002-2004, Fox Chase Cancer Center, Philadelphia, PA, USA.
• Post-Doctoral Fellowship: 2004-2008, Medical University of South Carolina, Charleston, SC, USA.

Employment:

• Research Assistant Professor: 2008-Present, Medical University of South Carolina, Charleston, SC, USA.

Research Interests:

•  Transcriptional regulation of cancer progression and the drug resistance phenotype

Publications:

• Moussa, O., Feldman, R., Fraig, M., Turner, D.P, and Watson, D.K.: PDEF-dependent  modulation of gene expression regulates colon cancer progression. Submitted.
• Moussa, O., Findlay, V, Turner, D.P, Fraig, M., Watson, D.K.  Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.Submitted.
• Schaefer, J.S., Jiang, J., Shi, H.Y., Sriraman, V., Turner, D.P., Watson, D.K., Richards, J., and Ming Zhang. (2008). PDEF expression inhibits breast cancer growth in vitro and in vivo. Submitted.
• V.J. Findlay, D.P. Turner, O. Moussa, and D.K. Watson. (2008) miRNA-mediated regulation of PDEF in breast cancer. Accepted with revision Cancer Res.
• Turner, D.P, Findlay, V.J., Moussa, O, and Watson, D.K. (2008). Global gene expression analysis identifies PDEF regulatory circuits during metastatic progression. Mol, Biol. Cell in press.
• Turner, D.P and Watson, D.K. (2008). ETS transcription factors – Oncogenes and tumor suppressor genes that drive prostate cancer. Expert Rev. Anticancer Ther.8(1), 33–42.
• Turner, D.P., Findlay, V.J., Moussa, O., and Watson, D.K. (2007). Defining ETS Transcription Regulatory Networks and their Contribution to Breast Cancer Progression. J. Cell. Biochem 102(3): 549–559.
• Turner, D.P., Moussa, O., Sauane, M., Fisher, P.B., and Watson, D.K. (2007) Prostate-Derived ETS Factor Is a Mediator of Metastatic Potential through the Inhibition of Migration and Invasion in Breast Cancer. Cancer Res 67: (4), 1618-1625.
• Turner, D.P., Cortellino, S., Schupp, J.E., Caretti, E., Loh, T., Kinsella, T.J. and Bellacosa, A. (2006) The DNA N-glycosylase MED1 exhibits preference for halogenated. pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 66: (15), 7686-7693.
• Cortellino, S., Turner, D.P., Albino, D., and Bellacosa, A. (2003). The base excision enzyme MED1 mediates DNA damage response to anti-tumor drugs by maintaining the integrity of the mismatch repair system. PNAS, 100 (25) 15071-6 (Front cover feature and commentary published in same issue).
• Turner, D.P. and Bellacosa, A. (2003). Insights into DNA recombination from the structure of a RAD51-BRCA2 complex – A critical commentary. Women’s Oncol. Rev. 3: 43-45.
• Cortellino, S., Turner, D.P., Albino, D. and Bellacosa, A. (2004). Induction of deoxyribonucleic Acid damage by alkylating agents. Methods Mol Biol. 285:121-6.
• Cortellino, S., Turner, D.P. and Bellacosa, A. (2004). Induction of Deoxyribonucleic Acid Damage by gamma Irradiation. Methods Mol. Biol. 285: 127-32.
• Turner, D.P., Yeung, A.T. and Bellacosa, A. (2004). Ultraviolet irradiation of cells. Methods Mol. Biol. 285: 133-138.
• Gonzalez-Nicieza, R., Turner, D.P. and Connolly, B.A. (2001). DNA Binding and Cleavage Selectivity of the E.coli DNA G:T mismatch endonuclease (vsr protein). J. Mol. Biol. 310 (3), 501-508.
• Turner, D.P. and Connolly, B.A. (2000). Interaction of the E.coli DNA G:T-mismatch Endonuclease (vsr protein) with Oligonucleotides Containing its Target Sequence. J Mol. Biol. 304 (5): 765-778.
• Curtin, N.J. and Turner, D.P. (1999). Dipyridamole-mediated Reversal of Multidrug Resistance in MRP Over-expressing Human Lung Carcinoma Cells In Vitro. Euro. J. Cancer. 35 (6): 1020-1026.